BLT2, a leukotriene B4 receptor 2, as a novel prognostic biomarker of triple-negative breast cancer.

BLT2, a leukotriene B4 receptor 2, as a novel prognostic biomarker of triple-negative breast cancer. BMB Rep. 2018 Jun 14;: Authors: Park J, Jang JH, Park GS, Chung Y, You HJ, Kim JH Abstract Triple-negative breast cancer (TNBC) is considered to be a notorious type of cancer due to its aggressive metastatic potential and poor prognosis. Recent evidence suggests that BLT2, a low-affinity LTB4 receptor is critically associated with the phenotypes of TNBC cells, including invasion, metastasis, and survival. Furthermore, in a group of 545 breast cancer patients with metastasis, we observed that the high-BLT2 subgroup had a lower disease-free-survival rate than the low-BLT2 subgroup. Thus, we theorized that anti-BLT2 strategies could facilitate the development of new therapies used for TNBC. This review focuses on recent discoveries regarding BLT2 and its roles in as a novel prognostic biomarker in TNBC. PMID: 29898809 [PubMed - as supplied by publisher]
Source: BMB Reports - Category: Biochemistry Authors: Tags: BMB Rep Source Type: research